WReSTOR IOL +3.0 D (model SN6AD1, Alcon, Fort Worth, Texas) was approved by the U.S. FDA, the physician labeling presented three-month outcomes for patients in the clinical trials. The new package insert contains six-month data, comparing outcomes of patients with bilateral +3.0 D IOLs against outcomes of patients with bilateral +4.0 D IOLs (Alcon). Bret L. Fisher, M.D., Eye Center of North Florida, Panama City, Fla., who participated as an investigator in the clinical trials, discussed the new labeling.
- Longer-term outcomes now available: 6-month clinical trials of the AcrySof IQ ReSTOR IOL +3.0 D
- Surgeon’s IOL of choice
- Surgeon prefers toric IOLs to LRIs for astigmatism management
- Preparation key to success with elective IOLs
- Peer-reviewed publications from around the world: The AcrySof IQ ReSTOR IOL +3.0 D
- New OVD strategies for toric IOL implantation